German CVC as most active corporate investor in the European life sciences sector
With 44 deals, the corporate venture arm of Boehringer Ingelheim was the most active...
FCF Biotech Venture Capital Monitor – USA 04/2022 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture...
FCF Interest & Corporate Loan Monitor May 2022 published
FCF Fox Corporate Finance GmbH is pleased to publish the new “FCF Interest &...
FCF Life Sciences co-organized “ACCESS CHINA Biotech Forum – Sommer Showcase 2022”
FCF co-organized, together with its partner YAFO Capital, the “ACCESS CHINA Biotech Forum” which...
What are the top 5 biggest M&A deals of 2021 so far?
With 2021 coming to a close, we’re taking the time to look back on...
Valuing 21st Century Businesses-Part 10
By now, I hope, we can all agree that 21st Century Business Models need...
What is a subsidiary?
You might be completely unaware that some of your favourite companies are actually just...
symptoom van de objectivering van het privaatrecht, op zijn beurt symptoom van het toegenomen belang van onstoffelijke organisaties – Corporate Finance Lab
J. Vananroye, “Respecteert het overgangsrecht van het WVV de rechtmatige verwachtingen”, in Liber Amicorum...
MAZARO’s IPO : a source of inspiration for capital-intensive scale-ups & SMEs
The post MAZARO’s IPO : a source of inspiration for capital-intensive scale-ups & SMEs...
Zinloos geweld? Over gemeen vennootschapsrecht en lastgeving in het WVV – Corporate Finance Lab
Vooraf Xavier Dieux was de eerste name partner van het kantoor waar ik in...